While anti-VEGF drugs are effective in reducing BRB pathology and improving visual acuity in some patients [14,15], the average gain of visual acuities is not sustained for patients with long-term anti-VEGF treatment for neovascular AMD and diabetic macular edema [16,17,18]. Here, VEGFA is linked to diabetic macular edema.